Sodium channel blockers: A patent review (2010-2014)

Expert Opinion on Therapeutic Patents

Volumn 25, Issue 3, 2015, Pages 279-290

  Zuliani, Valentina ^a   Rapalli, Alberto ^a   Patel, Manoj K ^b   Rivara, Mirko ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Chronic pain; Neuropathic pain; Sodium channel blockers; Sodium channel isoforms

Indexed keywords

AMIDE; ARYL CARBOXAMIDE DERIVATIVE; BENZENE SULFONAMIDE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; BENZOXAZOLINONE SULFONAMIDE DERIVATIVE; DIHYDROBENZOXAZINE SULFONAMIDE DERIVATIVE; INDAZOLE DERIVATIVE; INDAZOLO SULFONAMIDE DERIVATIVE; INDOLE DERIVATIVE; METHYLSULFONYLBENZAMIDE DERIVATIVE; PICOLINAMIDE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLOPYRIDINE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDINYL DIAZA SPIRO[4.4]NONANE DERIVATIVE; PYRIDINYLMORPHOLINONE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; PYRROLO BENZO DIAZINE DERIVATIVE; PYRROLOPYRIDINONE DERIVATIVE; QUINAZOLINE DERIVATIVE; SODIUM CHANNEL BLOCKING AGENT; SPIRO COMPOUND DERIVATIVE; SULFONAMIDE; TETRAHYDROQUINOXALINE SULFONAMIDE DERIVATIVE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; VOLTAGE GATED SODIUM CHANNEL;

ANALYTIC METHOD; ELECTROPHYSIOLOGY; FLUORESCENCE RESONANCE ENERGY TRANSFER; FLUORESCENT IMAGING PLATE READER ASSAY; FLUX ASSAY; HUMAN; NONHUMAN; PATCH CLAMP TECHNIQUE; REVIEW; ANIMAL; DRUG DESIGN; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATENT;

ANIMALS; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; PATENTS AS TOPIC; SODIUM CHANNEL BLOCKERS; VOLTAGE-GATED SODIUM CHANNELS;

EID: 84922767042     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.995628     Document Type: Review

References (66)

1. Hille B. Ionic channels of excitable membranes. 3rd ed. MA: Sinauer; Sunderland: 2001
2. Lehman-Horn F, Jurkat-Rott K. Voltage-gated ion channels and hereditary disease. Physiol Rev 1999;79(4):1317-72
3. Catterall WA, Dib-Hajj S, Meisler MH, et al. Inherited neuronal ion channelopathies: new windows on complex neurological diseases. J Neurosci 2008;28(46):11768-77
4. Bagal SK, Brown AD, Cox PJ, et al. Ion channels as therapeutic targets: a drug discovery perspective. J Med Chem 2013;56(3):593-624
5. Wickenden A, Priest B, Erdemli G. Ion channel drug discovery: challenges and future directions. Future Med Chem 2012;4(5):661-79
6. Peters CH, Ruben PC. Introduction to sodium channels. Handb Exp Pharmacol 2014;221:1-6
7. Catterall WA. Structure and function of voltage-gated sodium channels at atomic resolution. Exp Physiol 2014;99(1):35-51
8. Noda M, Ikeda T, Suzuki T, et al. Expression of functional sodium channels from cloned cDNA. Nature 1986;322(6082):826-8
9. Kyle DJ, Ilyin VI. Sodium channel blockers. J Med Chem 2007;50(11):2583-8
10. Patino G, Isom LL. Electrophysiology and beyond: multiple roles of Na+ channel-subunits in development and disease. Neurosci Lett 2010;486(2):53-9
11. Isom LL, De Jongh KS, Patton DE, et al. Primary structure and functional expression of the b1 subunit of the rat brain sodium channel. Science 1992;256(5058):839-42
12. Isom LL, Ragsdale DS, De Jongh KS, et al. Structure and function of the b2 subunit of brain sodium channels, a transmembrane glycoprotein with a CAM motif. Cell 1995;83(3):433-42
13. Calhoun JD, Isom LL. The role of non-pore-forming b subunits in physiology and pathophysiology of voltage-gated sodium channels. Handb Exp Pharmacol 2014;221:51-89
14. Zheng W, Spencer RH, Kiss L. High throughput assay technologies for ion channel drug discovery. Assay Drug Dev Technol 2004;2(5):543-52
15. Raqualia Pharma, Inc. Pyrazolopyridine derivatives as TTX-S blockers. WO068988; 2014
16. Shionogi & Co. Pyridinil morpholinone derivative and drug composition containing same. WO161929; 2013
17. Convergence Pharmaceutical Ltd. (Pyridin-2-yl)-1, 7-diaza-spiro[4.4]nonane-6-one compounds as voltage-gated sodium channels modulators. WO093497; 2013
18. Convergence Pharmaceutical Ltd. (Pyridin-2-yl)-1, 7-diaza-spiro[4.4]nonane-6-one compounds as voltage-gated sodium channels modulators. WO093496; 2013
19. Purdue Pharma LP. Pyridine compounds and the uses thereof. WO035421; 2012
20. Purdue Pharma LP. Pyridine compounds as sodium channel blockers. WO007836; 2012
21. Purdue Pharma LP. Substituted pyridines as sodium channel blockers. WO136170; 2013
22. Purdue Pharma LP. Quaternized amines as sodium channel blockers. WO064884; 2013
23. Glaxo Group Ltd. Voltage-gated sodium channel blockers. WO006596; 2013
24. Raquakia, Pharma, Inc. Pyrrolopyridinone derivatives as TTX-S blockers. WO161312; 2013
25. Raqualia Pharma, Inc. Acyl piperazine derivatives as TTX-S blockers. WO020567; 2012
26. Purdue Pharma LP. Pyrimidines as sodium channel blockers. WO030665; 2013
27. Purdue Pharma LP. Pyrimidine diol amides as sodium channel blockers. WO072758; 2013
28. Hunskaar S, Fasmer OB, Hole K. Formalin test in mice, a useful technique for evaluating mild analgesics. J Neurosci Methods 1985;14(1):69-76
29. Schering Corp. Cyclopropyl-spiro-piperidines useful as sodium channel blockers. WO047703; 2012
30. Vertex Pharmaceutical Incorp. Chroman-spirocyclic piperidine amides as modulators of ion channels. WO112743; 2012
31. Concert Pharmaceutical, Inc. 2-Oxo-1-pyrrolidine derivatives. WO002869; 2010
32. Amgen, Inc. Inhibitors of voltage-gated sodium channels. WO022055; 2010
33. University of Greenwich. Cyclo triazo sodium channel blockers. WO004196; 2011
34. University of Greenwich. Cyclo triazo sodium channel blockers. GB2471729; 2011
35. University of Greenwich. Cyclo triazo sodium channel blockers. GB2471713; 2011
36. Allergan, Inc. Benzimidazole derivatives as selective blockers of persistent sodium current. WO101911; 2013
37. Allergan, Inc. Benzimidazole derivatives as selective blockers of persistent sodium current. WO101929; 2013
38. Purdue Pharma LP. Aryl substituted indoles and the use thereof. WO158108; 2011
39. University College London. Indazole derivatives and their use for blockading voltage dependent sodium channels. WO061469; 2011
40. Purdue Pharma LP. Quinazoline compounds as sodium channel blockers. WO046132; 2012
41. Schering Corp. Methods for using pyrrolo-benzo-1, 4-diazines as sodium channel blockers. WO151597; 2010
42. Amgen, Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain. WO 103196; 2011
43. Raqualia Pharma, Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers. WO137351; 2010
44. Raqualia Pharma, Inc. Aryl carboxamide derivatives as TTX-S blockers. WO058766; 2011
45. Raqualia Pharma, Inc. Amide derivatives as TTX-S blockers. WO161308; 2013
46. Raqualia Pharma, Inc. Picolinamide derivatives as TTX-S blockers. WO016234; 2011
47. Xenon Pharmaceutical, Inc. Spiro-oxindole compounds and their use as therapeutic agents. WO045197; 2010
48. Xenon Pharmaceutical, Inc. Spiro-oxindole-derivatives as sodium channel blockers. WO078307; 2010
49. Xenon Pharmaceutical, Inc. Spiroheterocyclic compounds and their uses as therapeutic agents. US799798; 2010
50. Xenon Pharmaceutical, Inc. Spiro compounds and their uses as therapeutic agents. WO132352; 2010
51. Merck Sharp & Dohme Corp. N-substituted indazolo sulfonamide compounds with selective activity in voltage-gated sodium channels. WO066491; 2014
52. Merck Sharp & Dohme Corp. Benzoxazolinone compounds with selective activity in voltage-gated sodium channels. WO063459; 2013
53. Merck Sharp & Dohme Corp. Benzoxazolinone compounds with selective activity in voltage-gated sodium channels. WO066490; 2014
54. Amgen, Inc. Dihydrobanzoxazine and tetrahydroquinoxaline sodiun channel inhibitors. WO122897; 2013
55. Pfitzer Ltd. Chemical compounds. WO007877; 2012
56. Pfitzer Ltd. Sulfonamide derivatives. WO088315; 2013
57. Pfitzer Ltd. Chemical compounds. WO004706; 2012
58. Pfitzer Ltd. Chemical compounds. WO004714; 2012
59. Xenon Pharmaceutical, Inc. Benzenesulfonamide compounds and their uses as therapeutic agents. WO064983; 2013
60. Xenon Pharmaceutical, Inc. Biaryl ether sulfonamides and their use as therapeutic agents. WO064984; 2013
61. Daewoong Pharmaceutical Co. Sodium channel blockers, preparation method thereof and use thereof. WO061970; 2014
62. Vertex Pharmaceutical Incorp. Heterocyclic derivatives as modulators of ion channels. WO002956; 2010
63. University of Utah Research Foundation. Sodium channel sensitive conopeptides and analogs, including compositions andf methods thereof. WO15800; 2013
64. Bagal SK, Chapman ML, Marron BE, et al. Recent progress in sodium channel modulators for pain. Bioorg Med Chem Lett 2014;24(16):3690-9
65. Zakrzewska JM, Palmer J, Ettlin DA, et al. Novel design for a Phase IIa placebo-controlled, double-blind randomized withdrawal study to evaluate the safety and efficacy of CNV1014802 in patients with trigeminal neuralgia. Trials 2013;14:402-11
66. Nantermet PG, Henze DA. Recent advances toward pain therapeutics. Annu Rep Med Chem 2011;46:19-32